9,272 results match your criteria American journal of hematology[Journal]


Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis.

Am J Hematol 2019 Feb 14. Epub 2019 Feb 14.

University of Texas MD Anderson Cancer Center, Houston, TX.

The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher-risk populations with relapsed/refractory (R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated patients based on prior lines of therapy, including after ibrutinib discontinuation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25436DOI Listing
February 2019

Phase II study of carfilzomib and dexamethasone (Kd) therapy for newly diagnosed multiple myeloma.

Am J Hematol 2019 Feb 10. Epub 2019 Feb 10.

Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.

Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myeloma. Kd has not previously been evaluated in newly diagnosed multiple myeloma (NDMM). We report a single-arm phase 2 study of 72 patients with NDMM to evaluate the efficacy and tolerability of Kd induction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25435DOI Listing
February 2019
1 Read
3.798 Impact Factor

Using an Old Test for New Tricks: Measuring Direct Oral Anti-Xa Drug Levels by Conventional Heparin-Calibrated Anti-Xa Assay.

Am J Hematol 2019 Feb 7. Epub 2019 Feb 7.

Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25434DOI Listing
February 2019

Social Media Discussions Provide New Insight about Perceptions of Hydroxyurea in the Sickle Cell Community.

Am J Hematol 2019 Feb 7. Epub 2019 Feb 7.

Division of General Internal Medicine, Department of Medicine, University of Pittsburgh.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25430DOI Listing
February 2019
1 Read

Identifying Leukemia-Associated Immunophenotype-based Individualized Minimal Residual Disease in Acute Myeloid Leukemia and its Prognostic Significance.

Am J Hematol 2019 Feb 7. Epub 2019 Feb 7.

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, 197 Rui Jin Road II, Shanghai, China.

Based on the leukemia-associated immunophenotypes (LAIPs), minimal residual disease (MRD) related to the outcome can be detected by multiparameter flow cytometry in acute myeloid leukemia (AML) patients. Although 0.1% was commonly used as a cutoff value, measurable MRD or MRD level below 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25431DOI Listing
February 2019
1 Read
3.798 Impact Factor

BMI percentile is an independent predictor of increase in lung function in children with sickle cell anemia.

Am J Hematol 2019 Feb 7. Epub 2019 Feb 7.

Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25433DOI Listing
February 2019
1 Read

Clinicopathologic Features, Management and Outcomes of Plasmablastic Lymphoma: A Ten-Year Experience.

Am J Hematol 2019 Feb 7. Epub 2019 Feb 7.

Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25432DOI Listing
February 2019

CAR T cell immunotherapy for Multiple Myeloma. A review of current data and potential clinical applications.

Am J Hematol 2019 Feb 7. Epub 2019 Feb 7.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients despite significant improvements achieved with modern therapy. Tumor evasion is a key process in the pathogenesis of MM and a compromised immune system is associated with more aggressive forms of the disease. In contrast, the emergence of myeloma-specific immune responses after both autologous and allogeneic stem cell transplantation is associated with better prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25428DOI Listing
February 2019

White Matter Has Impaired Resting Oxygen Delivery in Sickle Cell Patients.

Am J Hematol 2019 Jan 29. Epub 2019 Jan 29.

Department of Biomedical Engineering, University of Southern California Engineering School, Los Angeles, California.

Although modern medical management has lowered overt stroke occurrence in patients with sickle cell disease (SCD), progressive white matter (WM) damage remains common. It is known that cerebral blood flow (CBF) increases to compensate for anemia, but sufficiency of cerebral oxygen delivery, especially in the WM, has not been systematically investigated. Cerebral perfusion was measured by arterial spin labeling in 32 SCD patients (age range: 10-42 years old, 14 males, 7 with HbSC, 25 HbSS) and 25 age and race-matched healthy controls (age range: 15-45 years old, 10 males, 12 with HbAS, 13 HbAA); 8/24 SCD patients were receiving regular blood transfusions and 14/24 non-transfused SCD patients were taking hydroxyurea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25423DOI Listing
January 2019
3 Reads

Unusual presentations of sitosterolemia limited to hematological abnormalities: A report of 4 cases presenting with stomatocytic anemia and thrombocytopenia with macrothrombocytes.

Am J Hematol 2019 Jan 29. Epub 2019 Jan 29.

Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25427DOI Listing
January 2019
1 Read

How we diagnose and manage altered oxygen affinity hemoglobin variants.

Am J Hematol 2019 Jan 28. Epub 2019 Jan 28.

Division of Hematology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Altered oxygen affinity variant hemoglobins (Hbs) are caused by mutations of the globin genes. Changes in Hb oxygen affinity shift the oxygen dissociation curve, and can be identified by abnormal p50 measurements of patient red blood cells. Variants are categorized as either low oxygen affinity (high p50) or high oxygen affinity (low p50). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25425DOI Listing
January 2019

A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.

Am J Hematol 2019 Jan 28. Epub 2019 Jan 28.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25426DOI Listing
January 2019

Erythrocyte ATP, a possible therapeutic approach for sickle cell disease.

Authors:
Joseph F Hoffman

Am J Hematol 2019 Jan 25. Epub 2019 Jan 25.

Department of Cellular and Molecular Physiology, Yale University, School of Medical, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25419DOI Listing
January 2019

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.

Am J Hematol 2019 Jan 25. Epub 2019 Jan 25.

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR T cells are then expanded for clinical use and infused back into the patient's body to attack and destroy chemotherapy-resistant cancer. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25418
Publisher Site
http://dx.doi.org/10.1002/ajh.25418DOI Listing
January 2019
12 Reads

Antigen excess pitfall for free light chains measurements solved by ELISA assay.

Am J Hematol 2019 Jan 25. Epub 2019 Jan 25.

Biochemistry and Molecular Biology Department, University of Lille CHU, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25422DOI Listing
January 2019

CARs of The Future.

Am J Hematol 2019 Jan 25. Epub 2019 Jan 25.

Memorial Sloan Kettering Cancer Center, United States.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25416
Publisher Site
http://dx.doi.org/10.1002/ajh.25416DOI Listing
January 2019
4 Reads

Heritability of fetal hemoglobin, white cell count, and other clinical traits from a sickle cell disease family cohort.

Am J Hematol 2019 Jan 25. Epub 2019 Jan 25.

Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Sickle cell disease (SCD) is the most common monogenic disorder in the world. Notably, there is extensive clinical heterogeneity in SCD that cannot be fully accounted for by known factors, and in particular, the extent to which the phenotypic diversity of SCD can be explained by genetic variation has not been reliably quantified. Here, in a family-based cohort of 449 patients with SCD and 755 relatives, we first show that 5 known modifiers affect 11 adverse outcomes in SCD to varying degrees. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25421
Publisher Site
http://dx.doi.org/10.1002/ajh.25421DOI Listing
January 2019
8 Reads

Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts.

Am J Hematol 2019 Jan 25. Epub 2019 Jan 25.

Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital & Peking University Institute of Hematology, Beijing, China.

This study evaluated the effects of pretransplantation minimal residual disease (pre-MRD) on outcomes of patients with acute lymphoblastic leukemia (ALL) who underwent unmanipulated haploidentical stem cell transplantation (haplo-SCT). A retrospective study including 543 patients with ALL was performed. MRD was determined using multiparametric flow cytometry. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25417
Publisher Site
http://dx.doi.org/10.1002/ajh.25417DOI Listing
January 2019
4 Reads

Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.

Primary vitreoretinal lymphoma (PVRL) is a subset of primary CNS lymphoma that presents as isolated ocular disease without brain involvement. Although ocular radiotherapy (RT) is an effective treatment for PVRL, the optimal treatment is uncertain. PVRL may later involve the brain in 56%-85% of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25414DOI Listing
January 2019
1 Read

Progression with clinical features is associated with worse subsequent survival in multiple myeloma.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Response rate and survival in multiple myeloma (MM) has improved in the era of proteasome inhibitors and immunomodulatory drugs. However, most patients eventually relapse with biochemical progression (BP) alone or with clinical features of end-organ damage (CP: clinical progression), without or without extramedullary (EM) disease. We conducted a retrospective cohort study of 252 patients with MM experiencing first relapse (time, T ) to evaluate survival following CP with and without EM as a function of BP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25415DOI Listing
January 2019
2 Reads

Benda-EAM prior to ASCT and renal toxicity: Much ado about nothing.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Hematology and Hematopoietic Stem Cell Transplant Center, AORMN, Pesaro, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25413DOI Listing
January 2019
1 Read

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25412DOI Listing
January 2019
3 Reads

Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Baylor College of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Houston, Texas.

Immune thrombocytopenia (ITP) is the most common autoimmune cytopenia in children. Approximately, 25% of patients develop chronic disease, which may be unpredictable and challenging to treat. It is not currently possible to predict at the time of presentation which patients will have chronic disease or will experience symptoms requiring second-line therapy defined as treatment beyond corticosteroids, intravenous immunoglobulin, or Rh immune globulin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25409DOI Listing
January 2019
3 Reads

Be ever cautious until the truth is proven.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Hematology Institute, University Hospital, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25410DOI Listing
January 2019
1 Read

Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Department of Medicine, Division of Medical Oncology, University of Washington Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25411DOI Listing
January 2019
2 Reads

A multi-institutional comparison of younger and older adults with sickle cell disease.

Am J Hematol 2019 Jan 20. Epub 2019 Jan 20.

Division of Hematology, Duke University School of Medicine, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25405DOI Listing
January 2019
1 Read

Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014.

Am J Hematol 2019 Jan 20. Epub 2019 Jan 20.

School of Public Health, Curtin University, Perth, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25407
Publisher Site
http://dx.doi.org/10.1002/ajh.25407DOI Listing
January 2019
3 Reads

Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.

Am J Hematol 2019 Jan 16. Epub 2019 Jan 16.

Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.

Chimeric antigen receptor modified T (CAR-T) cell therapy against the CD19 antigen has revolutionized the therapeutic landscape for patients with relapsed, refractory B cell non-Hodgkin lymphoma (NHL). Currently, there are two FDA approved products (axicabtagene ciloleucel and tisagenlecleucel) for B cell NHL, with several other constructs under clinical investigation. This review will focus on the clinical outcomes, toxicity profile, and differences among candidate CD19 CAR-T cell products for major subtypes of B cell NHL including diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25403DOI Listing
January 2019
3 Reads

Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis.

Am J Hematol 2019 Jan 16. Epub 2019 Jan 16.

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25404DOI Listing
January 2019
8 Reads
3.798 Impact Factor

A mummy emerges from the grave: Scurvy confounding the clinical presentation of a child with Fanconi anemia.

Am J Hematol 2019 Jan 13. Epub 2019 Jan 13.

Division of Pediatric Hematology, Oncology & HSCT Center, Department of Pediatrics, Erciyes University, Faculty of Medicine, Kayseri, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25402DOI Listing
January 2019
3 Reads

Calculator-free point-of-care prognostication in myelodysplastic syndromes.

Am J Hematol 2019 Jan 13. Epub 2019 Jan 13.

Divisions of Hematology, Departments of Internal and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25400
Publisher Site
http://dx.doi.org/10.1002/ajh.25400DOI Listing
January 2019
5 Reads

Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study.

Am J Hematol 2019 Jan 13. Epub 2019 Jan 13.

Division of Hematology/Oncology, Department of Pediatrics, UCSF Benioff Children's Hospital of Oakland, Oakland, California.

We conducted a multicenter pilot investigation of the safety and feasibility of bone marrow transplantation (BMT) in adults with severe sickle cell disease (SCD) (NCT 01565616) using a reduced toxicity preparative regimen of busulfan (13.2 mg/kg), fludarabine (175 mg/m ) and thymoglobulin (6 mg/kg) and cyclosporine or tacrolimus and methotrexate for graft-vs-host disease (GVHD) prophylaxis. Twenty-two patients (median age 22 years; range 17-36) were enrolled at eight centers. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25401
Publisher Site
http://dx.doi.org/10.1002/ajh.25401DOI Listing
January 2019
10 Reads

CAR-T cells beyond CD19, UnCAR-Ted territory.

Am J Hematol 2019 Jan 11. Epub 2019 Jan 11.

Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.

CAR-T cells have made dramatic inroads in targeting CD19-positive B-cell malignancies. This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25398DOI Listing
January 2019
2 Reads

Allogeneic CAR T cell therapies for leukemia-R1.

Authors:
Waseem Qasim

Am J Hematol 2019 Jan 11. Epub 2019 Jan 11.

University College London, Great Ormond Street Institute of Child Health, London, United Kingdom.

Allogeneic chimeric antigen receptor T (CAR T) cells can offer advantages over autologous T cell therapies, including the availability of "fit" cells for production, and elimination of risks associated with inadvertent transduction of leukemic blasts. However, allogeneic T cell therapies must address HLA barriers and conventionally rely on the availability of a suitable HLA-matched donor if graft-vs-host-disease and rejection effects are to be avoided. More recently, the incorporation of additional genome editing manipulations, to disrupt T cell receptor expression and address other critical pathways have been explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25399DOI Listing
January 2019
2 Reads

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Am J Hematol 2019 Jan 8. Epub 2019 Jan 8.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO), a humanized CD22 antibody conjugated to calicheamicin, in the phase 3, open-label, randomized INO-VATE trial. Data as of March 8, 2016, are presented in this analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25394DOI Listing
January 2019
8 Reads

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Am J Hematol 2019 Jan 7. Epub 2019 Jan 7.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

Disease Overview: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS-RS) and RARS with thrombocytosis (RARS-T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T).

Diagnosis: MDS-RS is a lower-risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥ 15% BM RS (≥5% in the presence of SF3B1 mutations). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25397
Publisher Site
http://dx.doi.org/10.1002/ajh.25397DOI Listing
January 2019
19 Reads

Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation.

Am J Hematol 2018 Dec 30. Epub 2018 Dec 30.

EBMT Paris study office/CEREST-TC, Paris, France.

Therapy-related acute myeloid leukemia (t-AML) arises as a late complication following antecedent solid tumors or hematologic diseases and their associated treatments. There are limited data regarding risk factors and outcomes following allogeneic hematopoietic cell transplantation (HCT) for t-AML following a prior solid tumor, and furthermore, the impact of myeloablative (MAC) vs reduced-intensity conditioning (RIC) on survival is unknown. The acute leukemia working party (ALWP) of the European society for blood and bone marrow transplantation (EBMT) performed a large registry study that included 535 patients with t-AML and prior solid tumor who underwent first MAC or RIC allogeneic HCT from 2000-2016. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25395
Publisher Site
http://dx.doi.org/10.1002/ajh.25395DOI Listing
December 2018
5 Reads

Automated assays for von Willebrand factor activity.

Am J Hematol 2018 Dec 28. Epub 2018 Dec 28.

Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont.

von Willebrand factor (VWF) ristocetin cofactor activity (VWF:RCo) by platelet aggregometry has been considered the gold standard for evaluating the ability of VWF to bind platelets for over 40 years. Many automated systems no longer require platelets and rather rely on agglutination of latex particles. Automated methods of measuring VWF activity have improved performance characteristics and are performed on the same coagulation instruments used for routine testing via immunoturbidimetric methodology. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25393
Publisher Site
http://dx.doi.org/10.1002/ajh.25393DOI Listing
December 2018
6 Reads

Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.

Am J Hematol 2018 Dec 27. Epub 2018 Dec 27.

Division of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.

Background: In patients with diabetes mellitus, hyperfiltration precedes the development of albuminuria. Pediatric sickle cell anemia (SCA) patients have a high prevalence of hyperfiltration and albuminuria during early childhood and adolescence. We tested the hypothesis that hyperfiltration precedes the development of albuminuria in a longitudinal pediatric SCA cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25390DOI Listing
December 2018
3 Reads

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.

Am J Hematol 2018 Dec 27. Epub 2018 Dec 27.

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

Optimizing consolidation treatment in transplant-eligible newly diagnosed multiple myeloma patients in order to improve efficacy and bone-related outcomes is intriguing. We conducted an open-label, prospective study evaluating the efficacy and safety of bortezomib and lenalidomide (VR) consolidation after ASCT, in the absence of dexamethasone and bisphosphonates. Fifty-nine patients, who received bortezomib-based induction, were given 4 cycles of VR starting on day 100 post-ASCT. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25392
Publisher Site
http://dx.doi.org/10.1002/ajh.25392DOI Listing
December 2018
6 Reads

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Am J Hematol 2018 Dec 27. Epub 2018 Dec 27.

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

Trisomies of odd numbered chromosomes are seen in nearly half of patients with multiple myeloma (MM) and typically correlate with a hyperdiploid state and better overall survival (OS). We compared DNA ploidy of monoclonal plasma cells (as a surrogate for the presence of trisomies) assessed simultaneously by PCPRO (plasma cell proliferative index), a novel method that estimates DNA index by multi-parametric flow cytometry to fluorescence in situ hybridization (FISH) in 1703 patients with plasma cell disorders. The distribution of ploidy was hyperdiploid: 759 (45%), diploid 765 (45%), hypodiploid: 71 (4%), tetraploid/near-tetraploid: 108 (6%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25391DOI Listing
December 2018
2 Reads

High frequency of acquired aplastic anemia in Tanzania.

Am J Hematol 2018 Dec 27. Epub 2018 Dec 27.

Department of Haematology and Blood Transfusion, Muhimbili National Hospital and Muhimbili University of Health and Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25388DOI Listing
December 2018
1 Read

Voxelotor treatment of a patient with sickle cell disease and very severe anemia.

Am J Hematol 2018 Dec 27. Epub 2018 Dec 27.

Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25389DOI Listing
December 2018
3 Reads

Purpura fulminans from reduced protein S following cytomegalovirus and varicella infection.

Am J Hematol 2018 Dec 26. Epub 2018 Dec 26.

Penn State Health Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25386DOI Listing
December 2018
1 Read